Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP ...

Much of it has failed scientific scrutiny, dismissed as ineffective or unsafe once tested in laboratories. Occasionally, ...

In an age of constant distraction, reclaiming our lives may be less about unplugging — and more about plugging in with ...